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Abstract
Introduction: Pulmonary arterial hypertension (PAH), characterized by increased pulmonary artery pressures in the absence of elevated
pulmonary venous pressures, is a progressive disease associated with reduced exercise capacity and increased mortality risk. Current
treatments for PAH include nonspecific vasodilators, prostacyclin and related analogs, and endothelin receptor antagonists. Since
phosphodiesterase type 5 is highly expressed in pulmonary vascular tissues, agents that selectively inhibit phosphodiesterase type 5
activity induce pulmonary arterial vasodilatation, and are being developed for the treatment of PAH.
Aims: The purpose of this review is to evaluate the existing evidence for the use of tadalafil, a selective phosphodiesterase type 5
inhibitor, in PAH.
Evidence review: Data from erectile dysfunction populations indicate that tadalafil is well tolerated with an elimination half-life of
17.5 hours. Small pilot studies in patients with PAH of mixed etiology demonstrate that tadalafil reduces pulmonary vascular resistance
and is associated with improved clinical status. A multicenter, randomized, placebo-controlled clinical trial in patients with PAH is
currently recruiting patients.
Clinical potential: Based on existing studies of sildenafil, a related selective phosphodiesterase type 5 inhibitor in PAH, and the findings
of initial pilot studies, tadalafil appears to have excellent potential to provide therapeutic benefit in patients with pulmonary hypertension.
The long elimination half-life of tadalafil makes it suitable for once-daily dosing.
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Outcome measure Emerging evidence
Patient-oriented outcomes
Functional capacity Tadalafil improves functional capacity
Quality of life Tadalafil may improve quality of life
Mortality risk No evidence
Tolerability Tadalafil is as well tolerated as sildenafil in pulmonary arterial hypertension
Disease-oriented outcomes
Pulmonary vascular resistance Tadalafil selectively decreases pulmonary vascular resistance
Exercise capacity Improvement in exercise capacity with tadalafil comparable to that with sildenafil
Economic evidence
Cost effectiveness No evidenceScope, aims, and objectives
Tadalafil is a selective phosphodiesterase type 5 inhibitor
approved by the Food and Drug Administration (FDA) for the
treatment of erectile dysfunction (Carson 2006; Doggrell 2007;
Hatzimouratidis & Hatzichristou 2007). Tadalafil improves erectile
function by augmentation of cyclic guanosine monophosphate
(GMP) signaling in corpus cavernosum tissue. Since
phosphodiesterase type 5 is highly expressed in lung vasculature,
tadalafil may also offer therapeutic benefit as a pulmonary
vasodilator in patients with pulmonary arterial hypertension (PAH)
(Corbin et al. 2005; Hemnes & Champion 2006; Raja et al. 2006;
Sastry 2006).
The objective of this article is to review the available evidence for
the potential use of tadalafil in the treatment of PAH. In addition,
this article will provide an overview of the pathophysiology and
current treatment options for PAH. The clinical evidence in
support of the use of sildenafil, another phosphodiesterase type
5 inhibitor in PAH, will be also be reviewed.
Methods
Literature searches were conducted in the databases listed
below. The search terms were “tadalafil AND pulmonary AND
hypertension” with no search tags unless otherwise stated.
Results were limited to human studies in the English
language only.
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi,
1966 to date
• EMBASE, http://www.datastarweb.com, 1974 to date
• BIOSIS, http://www.datastarweb.com. Search term “(tadalafil
AND pulmonary hypertension) AND (LG=EN) AND
(PT=MEETING-ABSTRACT)”
• Scopus, http://www.scopus.com.
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm. All three
databases searched together. All fields searched
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm. Entire site searched
• Clinical trials database, http://www.clinicaltrials.gov
After removal of duplicates, a total of 28 citations were identified.
Records were manually reviewed and 21 citations were excluded
as nonsystematic reviews (n=15), citations that did not mention
clinical use of tadalafil in PAH (n=4), citations that duplicated
another report by the same authors (n=1), or citations not
available for review (n=1). No systematic reviews of tadalafil in
PAH have been published.
Inclusion criteria for the outcomes analysis of tadalafil in PAH
used an accepted scale of hierarchy of evidence (Table 1).
Introduction
Phosphodiesterases are a family of 11 metallophosphydrolase
enzyme isoforms that catalyze the metabolic breakdown of
second messenger cyclic nucleotides in numerous cell types
(Beavo 1995; Raja et al. 2006). Each phosphodiesterase isoform
has a distinct pattern of tissue distribution and cyclic nucleotide
substrate affinity. In vascular smooth muscle, phosphodiesterase
type 5 is the predominant isoform that mediates hydrolysis of
cyclic GMP. The type 5 isoform is a homodimeric enzyme with a
single catalytic binding site and regulatory binding site in each
component of the dimer (Blount et al. 2004).The catalytic site
hydrolyzes cyclic GMP to inactive 5’-guanosine monophosphate.
The regulatory domain contains an allosteric cyclic GMP binding
site and a regulatory phosphorylation site. Binding of cyclic GMP
to the regulatory domain enhances activity of the catalytic domain
and thereby provides a negative feedback inhibition mechanism
for control of cyclic GMP signaling. This same feedback
mechanism serves to increase catalytic domain binding affinity
of a pharmacologic antagonist as cyclic GMP levels rise
during pharmacologic inhibition of enzyme activity. In vascular
smooth muscle, augmented levels of cyclic GMP lead to
increased vasorelaxation.
The potential clinical utility of selective pharmacologic inhibition
of phosphodiesterase type 5 has been extensively evaluated in
clinical trials in men with erectile dysfunction (Carson 2006;
Doggrell 2007; Hatzimouratidis & Hatzichristou 2007). Normal
erectile function is critically dependent on nitric oxide-induced,
cyclic GMP-mediated vasorelaxation in corpus carvernosum, a
specialized form of smooth muscle in the penis. In men with
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Category Number of records
Full papers Abstracts
Initial search 28 0
records excluded 21
records included 70
Additional studies identified 00
Level 1 clinical evidence
(systematic review, meta analysis)
00
Level 2 clinical evidence (RCT) 00
Level ≥3 clinical evidence 3
trials other than RCT 0
case reports 4
Economic evidence 00
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review227
erectile dysfunction related to impaired nitric oxide signaling,
augmentation of cyclic GMP signaling with pharmacologic
inhibition of phosphodiesterase type 5 is associated with
improved erectile function. Three selective phosphodiesterase
type 5 inhibitors are currently approved by the FDA for the
treatment of erectile dysfunction (sildenafil, vardenafil, and
tadalafil). Although there are few existing data with direct
comparisons in clinical trials, these agents appear to be
comparable in their overall efficacy and safety profiles in men with
erectile dysfunction (Carson 2006; Doggrell 2007; Hatzimouratidis
& Hatzichristou 2007). However, there are known differences in
the molecular and clinical pharmacologic characteristics of these
agents that may impact their clinical utility in erectile dysfunction
and other disease states. All three agents are highly potent
inhibitors of phosphodiesterase type 5 (IC50 values for sildenafil,
vardenafil, and tadalafil are 3.9, 0.7, and 5 nM, respectively), with
distinct patterns of relative selectivity for other
phosphodiesterase isoforms (Carson 2006; Doggrell 2007).
Sildenafil and vardenafil have lower selectivity ratios with respect
to the type 6 isoform (range, 6- to 35-fold), while tadalafil has a
lower selectivity ratio for the type 11 isoform (range, 6- to 40-fold).
Since the type 6 isoform is expressed in rods and cones in retinal
tissues, partial inhibition of this isoform by sildenafil and vardenafil
may account for visual change side effects reported with these
agents. The type 11 isoform is known to be expressed in cardiac,
pituitary, and testes tissues, but the clinical sequelae of partial
inhibition of this isoform with tadalafil are unknown. When
compared with sildenafil and vardenafil, tadalafil has a slightly
slower onset of peak effect (peak plasma levels for tadalafil
120 min vs 60 min for sildenafil and vardenafil) and a much longer
elimination half-life (tadalafil 17.5 hours vs 3.8–3.9 hours for
sildenafil and vardenafil) (Carson 2006; Doggrell 2007).
Disease overview
PAH is a chronic disease of the pulmonary vasculature defined as
the presence of a mean pulmonary artery pressure >25 mmHg at
rest (or >30 mmHg during exercise) in the presence of mean
pulmonary capillary wedge pressure <15 mmHg (Galie et al. 2004;
Sastry 2006; Traiger 2007). The pathogenesis of this disorder is
complex and incompletely characterized. Increased pulmonary
artery blood pressures are associated with structural changes in
the pulmonary circulation characterized by pulmonary
arteriopathy (intimal thickening, medial hypertrophy, adventitial
thickening, and plexiform lesions), in-situ thrombosis, and
rarefaction of the microcirculation. Since the primary cause of
these structural and functional changes in the pulmonary
circulation is not discernible in many instances, the clinical
classification of PAH is based on the presence or absence of
associated clinical factors that are believed to contribute to
pathogenesis of disease (Table 2).
Clinical manifestations of PAH are related to the hemodynamic
effects of increased afterload on the right ventricle and systemic
manifestations of the comorbid conditions associated with
elevated pulmonary vascular resistance. Progressive exercise
intolerance, lower extremity edema, ascites, and syncope are
common clinical presentations. Although duplex
echocardiography is considered an excellent screening tool in
suspected cases, cardiac catheterization with direct
measurement of pulmonary artery pressures is required for
definitive diagnosis. PAH is associated with progressive right
ventricular failure and high mortality risk. Data from a national
registry demonstrated a median survival of 2.8 years after
diagnosis (D'Alonzo et al. 1991).
Vascular endothelial cells release a wide array of vasoactive
substances that play an important role in the normal regulation of
vasomotor tone, vascular structure, and blood pressure
homeostasis (Vane et al. 1990). Endothelium-derived nitric oxide
is a key regulatory molecule with potent vasorelaxation effects. In
lung circulation, nitric oxide is an important mediator of local
vasodilatation for matching of regional blood flows to regional
ventilation (Ghofrani et al. 2006). Its vasorelaxation actions are
mediated by activation of guanylyl cyclase and production of the
second messenger cyclic GMP in vascular smooth muscle.
Phosphodiesterase type 5 is highly expressed in lung tissues and
is the principal phosphodiesterase isoform responsible for
hydrolysis of cyclic GMP (Corbin et al. 2005). Dysregulation of the
nitric oxide system is thought to be an important factor
contributing to the pathogenesis of the structural and functional
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1. Pulmonary arterial hypertension
a. Idiopathic
b. Familial
c. Associated with:
i. Connective tissue disease
ii. Congenital systemic to pulmonary shunts
iii. Portal hypertension
iv. HIV infection
v. Drugs and toxins
vi. Other systemic disorders
2. Pulmonary hypertension associated with left-sided heart diseases
a. Left-sided atrial or ventricular heart disease
b. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung respiratory diseases
and/or hypoxia
a. Chronic obstructive lung disease
b. Interstitial lung disease
c. Sleep disordered breathing
d. Alveolar hypoventilation disorders
e. Chronic exposure to high altitude
f. Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or
embolic disease
a. Thromboembolic obstruction of proximal pulmonary arteries
b. Thromboembolic obstruction of distal pulmonary arteries
c. Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
5. Miscellaneous
a. Sarcoidosis, histiocytosis X, lymphangioma
HIV, human immunodeficiency virus.
Table 2 | Clinical classification of pulmonary arterial
hypertension (adapted from Galie 2004)changes in lung circulation in patients with PAH (Ghofrani et al.
2006; Hemnes & Champion 2006). Accordingly, augmentation of
nitric oxide signaling in vascular smooth muscle with selective
type 5 phosphodiesterase inhibition may be an effective
therapeutic strategy.
Current therapy options
Recent reports describe consensus clinical guidelines for the
diagnosis and treatment of PAH (Galie et al. 2004; Sastry 2006;
Traiger 2007). The treatment strategy for pulmonary hypertension
is based on the identification and treatment of underlying
conditions associated with the disease (connective tissue
disease, systemic to pulmonary shunts, parenchymal lung
disease, chronic thromboembolism), general supportive care to
prevent further thrombosis (e.g. long-term oral anticoagulation
therapy with warfarin), treating symptoms related to right
ventricular failure (e.g. with digoxin and diuretics), and
individualized use of several classes of vasodilating drugs to
reduce pulmonary vascular resistance. Specific treatment
algorithms are described in the consensus guidelines. Preliminary
data from short reports suggest that different classes of
vasodilating agents may be used together to provide additive
benefits. In patients with symptoms refractory to medical therapy,
other interventions including atrial septostomy and lung
transplantation may be considered.
Calcium channel blockers are recommended for long-term use in
the subset of patients who demonstrate an acute vasodilating
response to these agents during cardiac catheterization. The
acute hemodynamic effects may not accurately predict the long-
term clinical response in all patients, so follow-up surveillance of
the pulmonary vascular effects is recommended.
Prostanoids are prostacyclin analogs that mediate vasodilatation
by increasing levels of cyclic adenosine monophosphate in the
lung vasculature. These agents also have potent antiplatelet and
antiproliferative effects. Epoprostenol has a very short half-life
and can only be administered by continuous intravenous infusion.
Epoprostenol has been demonstrated to reduce pulmonary
vascular resistance, improve quality of life, and prolong survival in
severely ill patients (Sastry 2006). Its use is limited by the
necessity for chronic intravenous access and high rates of side
effects. Treprostinil, iloprost, and beraprost are related
compounds that can be given by other routes including
subcutaneous administration (treprostinil), inhalation (iloprost), or
orally (beraprost). Inhaled iloprost and subcutaneous and
intravenous treprostinil are approved by the FDA for the treatment
of PAH.
Bosentan is a nonselective endothelin-1 receptor antagonist that
has also been approved by the FDA for the treatment of PAH. This
agent blocks the potent vasoconstrictive and proliferative effects
of endothelin-1 in the pulmonary vasculature and has been shown
to decrease pulmonary vascular resistance and increase exercise
capacity (Sastry 2006). Ambrisentan and sitaxsentan are selective
endothelin-1 type A receptor antagonists that have also been
shown to decrease pulmonary vascular resistance and improve
exercise tolerance (Galie et al. 2005a; Barst et al. 2006). Use of
this class of agents is potentially limited by liver toxicity and the
need for contraception in both men and women. Ambrisentan
was recently approved by the FDA for once-daily use in patients
with PAH and appears to have reduced risk of hepatotoxicity
when compared with bosentan (Galie et al. 2005a).
Of particular relevance to the discussion of tadalafil in the
treatment of PAH, sildenafil is a selective phosphodiesterase type
5 inhibitor that is approved by the FDA for this indication (Hemnes
& Champion 2006; Raja et al. 2006). The clinical safety and
efficacy of sildenafil in PAH are described in two recent review
articles. A systematic review from the Cochrane Collaboration in
2004 reported on the efficacy of sildenafil in 77 subjects with
pulmonary hypertension derived from four randomized clinical
trials (two acute unblinded studies and two longer-term blinded
crossover studies of 2–6 weeks’ duration) (Kanthapillai et al.
2004). The authors concluded that the reviewed evidence
demonstrated that sildenafil has an acute pulmonary
vasodilatation effect and was associated with improvement in
symptoms during chronic use. However, interpretation of the
findings was limited by the small number of subjects and
heterogeneous nature of the underlying PAH. Raja and colleagues
published a more recent systematic review of the medical
literature in 2006 (Raja et al. 2006). Twenty-two clinical studies of
acute and chronic sildenafil therapy (alone or in combination with
other agents) in PAH were identified. These authors concluded
that sildenafil is an effective acute pulmonary vasodilator that is
associated with evidence of clinical improvement during chronic
use. Their conclusions are based primarily on a large, multicenter,
double-blind, randomized clinical trial of sildenafil versus placebo
in 278 patients with PAH of mixed etiology, including idiopathic
PAH (n=175), PAH associated with connective tissue diseases
(n=84), and surgically corrected left-to-right shunts (n=18) (Galie
et al. 2005b). Subjects with 6-min walking distance <100 m or
>450 m, and subjects receiving treatment with prostacyclin
analogs or bosentan were excluded from the study. Eligible
subjects were randomly assigned to placebo or one of three
doses of sildenafil (20, 40, or 80 mg) three times daily for
12 weeks. Sildenafil significantly increased the 6-min walk
distance (the prespecified primary endpoint) when compared with
placebo at 12 weeks (placebo-corrected change from baseline
+45 m for the 20 mg group, +46 m for the 40 mg group, and
+50 m for the 80 mg group; P<0.001 for each sildenafil group vs
placebo). The improvement in exercise capacity was consistent
across prespecified subgroups. Pulmonary vascular resistance
decreased significantly and functional capacity improved in
patients assigned to sildenafil when compared with placebo.
There were few serious adverse events during the 12-week study
and withdrawals from treatment were evenly distributed among
the treatment groups. Adverse events more commonly observed
during sildenafil administration when compared with placebo
were headache (sildenafil 42–49% vs placebo 39%), flushing
(sildenafil 9–15% vs placebo 4%), and dyspepsia (sildenafil
9–13% vs placebo 7%). Of the 265 subjects who completed the
12-week study, 259 entered an open-label, 52-week extension
period and received sildenafil 80 mg three times daily. Among
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222 patients in this extension phase treated with sildenafil for at
least 1 year, the improvement in exercise capacity was sustained
(change from baseline after 12 months +51 m). During this
uncontrolled extension phase, there were 14 deaths with a
calculated survival rate of 97%, substantially greater than the
expected survival rate of 71% based on historical controls (Sastry
2006). Since there was no evidence of a dose–response
relationship with respect to the primary endpoint of the study,
sildenafil was approved by the FDA for treatment of PAH at the
dose of 20 mg three times daily.
Unmet needs
It is well recognized that agents requiring greater than once-daily
dosing are associated with higher rates of therapy nonadherence
(Clifford-Middel 2004). Accordingly, development of an agent with
less-frequent dosing requirements is desirable. The longer
elimination half-life of tadalafil makes it suitable for potential
development as a once-daily agent for the treatment of PAH.
Outcomes achieved with tadalafil in clinical
development
Tadalafil is a selective phosphodiesterase type 5 inhibitor
approved by the FDA for the treatment of erectile dysfunction
(Carson 2006; Doggrell 2007; Hatzimouratidis & Hatzichristou
2007). Tadalafil is approved for use as single doses of 10–20 mg
for patients with erectile dysfunction. Several small studies have
investigated the effects of chronic dosing of tadalafil every
1–2 days in patients with erectile dysfunction (McMahon 2004;
Mirone et al. 2005; Porst et al. 2006). In these pilot studies,
tadalafil was well tolerated and associated with high rates of
improvement in erectile function.
It is uncertain whether selective phosphodiesterase type 5
inhibitors approved for the treatment of erectile dysfunction
(vardenafil and tadalafil) would provide benefits comparable to
sildenafil in patients with PAH. All three agents bind to the same
catalytic site in purified phosphodiesterase type 5 preparations
and provide comparable clinical improvement in erectile function
when compared with placebo in men with erectile dysfunction
(Blount et al. 2004; Carson 2006; Doggrell 2007; Hatzimouratidis
& Hatzichristou 2007). However, some differences in
pharmacodynamic profiles of these three agents have been
reported in isolated blood vessel preparations. Teixeira and
colleagues evaluated the effects of sildenafil, vardenafil, and
tadalafil on vasorelaxation in isolated rat aorta preparations. All
agents relaxed aortic rings with intact endothelium and increased
cyclic GMP levels compared with pretreatment baseline (Teixeira
et al. 2006). Removal of the endothelial cell layer from the aortic
ring preparation attenuated the maximum relaxation response to
sildenafil and tadalafil, but not vardenafil. Vardenafil, but not
sildenafil nor tadalafil, was also reported to significantly attenuate
contractions induced by calcium chloride. These findings suggest
that vardenafil has a distinct endothelium-independent
mechanism of action related to calcium handling in the rat aorta.
Tsai and colleagues studied the comparative effects of sildenafil,
vardenafil, and tadalafil in isolated rat pulmonary arteries (Tsai et
al. 2006). All three agents induced vasorelaxation in pulmonary
artery rings precontracted with phenylephrine, but only tadalafil
significantly attenuated hypoxia-induced vasoconstriction and
significantly attenuated hypoxia-induced upregulation of tumor
necrosis factor alfa and interleukin-1 beta messenger RNA.
Ghofrani and colleagues studied the comparative acute
hemodynamic effects of three different selective
phosphodiesterase inhibitors (sildenafil 50 mg, vardenafil
10–20 mg, and tadalafil 20–60 mg) in 60 patients, mean age
51 years, with PAH of mixed etiologies including idiopathic
pulmonary hypertension (n=46), Eisenmenger syndrome (n=7),
CREST syndrome (limited scleroderma comprising calcinosis,
Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly,
and telangiectasia) (n=4), portopulmonary hypertension (n=2), and
HIV-associated pulmonary hypertension (n=1) (Ghofrani et al.
2004). Exclusion criteria were secondary forms of pulmonary
hypertension and pregnancy or insufficient contraceptive
measures in women of childbearing age. The first 19 patients
enrolled received sildenafil 50 mg, and remaining patients were
randomly assigned to receive a single dose of vardenafil 10 or
20 mg, or tadalafil 20, 40, or 60 mg. All patients also received
inhaled nitric oxide before administration of their selective
phosphodiesterase type 5 inhibitor. Hemodynamic measurements
were made before and at periodic time intervals for 120 min after
study drug. All three phosphodiesterase inhibitors reduced
pulmonary vascular resistance when compared with pretreatment
values, with peak effects at 40–45 min for vardenafil, 60 min for
sildenafil, and 75–90 min for tadalafil. The ratio of pulmonary
vascular resistance to systemic vascular resistance (a measure of
the degree of selective pulmonary circulation vasodilatation) was
higher after vardenafil administration when compared with
sildenafil, tadalafil, and inhaled nitric oxide. Oxygen saturation
improved after sildenafil administration, but not after vardenafil or
tadalafil. These differences in some measures of clinical response
to selective phosphodiesterase type 5 inhibitors may be
attributable to known differences in potencies or other
pharmacologic properties of these agents, and/or clinical
differences in the patients assigned to each treatment group.
Since the number of subjects in each group is small, additional
studies are needed to better characterize the comparative
pharmacodynamic effects of these agents in PAH.
There are further limited data on the use of tadalafil in patients
with PAH. Several case reports provide anecdotal evidence of
acute and chronic reductions in pulmonary vascular resistance,
improved functional capacity and increased exercise capacity
after administration of tadalafil 10–20 mg every 36–48 hours
(Palmieri et al. 2004; Affuso et al. 2006; de Carvalho et al. 2006;
Deibert et al. 2007; Kim et al. 2007). There are two additional small
case series of patients with PAH treated with tadalafil.
Mukhopadhyay and colleagues studied the acute and chronic
effects of tadalafil at a dose of 1 mg/kg daily (maximum 40 mg
daily) in 16 patients (mean age 25 years) with symptomatic PAH
associated with Eisenmenger syndrome in an open-label,
uncontrolled study design (Mukhopadhyay et al. 2006). Patients
with World Health Organization (WHO) class IV symptoms,
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hypertension reversible with oxygen were excluded from the
study. When compared with pretreatment values, tadalafil
treatment significantly reduced pulmonary vascular resistance
90 min after the first dose (24.75ﾱ8.49 to 19.22ﾱ8.23 Wood units;
P<0.05) with further reductions after 12 weeks of therapy
(17.02ﾱ6.19 Wood units; P<0.05 vs 90-min value). The
vasodilatory effects of tadalafil were selective for the pulmonary
circulation, as evidenced by a significant decrease in the
pulmonary vascular resistance/systemic vascular resistance ratio
(1.09ﾱ0.34 pretreatment to 0.79ﾱ0.26 90 min after the first dose,
and 0.71ﾱ0.26 after 12 weeks of tadalafil treatment) and reduced
right-to-left shunt (1.71ﾱ0.92 pretreatment to 1.27ﾱ0.50 90 min
after the first dose, and 1.16ﾱ0.62 after 12 weeks of tadalafil
treatment). WHO functional class and submaximal exercise
capacity (assessed by 6-min walk distance) improved after
12 weeks of tadalafil therapy when compared with pretreatment
values (WHO class 2.31ﾱ0.47 pretreatment to 1.25ﾱ0.44; 6-min
walk distance 344.56ﾱ119.06 m pretreatment to 387.56ﾱ
117.18 m; both P<0.001).
Tay and colleagues reported a case series of 12 patients with PAH
of mixed etiology (four patients with idiopathic pulmonary artery
hypertension, four with Eisenmenger syndrome, and two with
connective tissue disease; mean age 45 years) in whom chronic
sildenafil therapy at a dose of 100–150 mg daily for 3–6 months
was switched to tadalafil 10–20 mg daily for 3–6 months (Tay et
al. 2007). All patients had a favorable response to sildenafil,
defined as a >10% improvement in the 6-min walk test distance
when compared with pretreatment baseline. Submaximal
exercise capacity assessed by the 6-min walking test, New York
Heart Association functional class, cardiac output estimated from
transthoracic duplex echocardiography studies, and health
function assessed by the Short-Form 36 (SF-36) score did not
change after the switch from sildenafil to tadalafil therapy.
Tadalafil was well tolerated with no adverse effects reported after
the switch from sildenafil.
The PHIRST-1 study is a randomized, double-blind placebo-
controlled study to determine the safety and efficacy of tadalafil in
patients with PAH (clinicaltrials.gov identifier NCT00125918). An
estimated 400 subjects with PAH will be treated with tadalafil or
placebo for 16 weeks. Patients >12 years of age with idiopathic
PAH or pulmonary hypertension associated with collagen
vascular disease, past anorexigen use, atrial septal defect, or
surgically repaired congenital shunt are eligible for the study. The
primary endpoint of the study is change from baseline 6-min walk
distance. Secondary endpoints include WHO functional class,
Borg dyspnea scale, cardiopulmonary hemodynamics, and
quality of life. After completion of the 16-week study, subjects
may be eligible to enroll in a 52-week extension phase
study (PHIRST-2).
Patient group/population
PAH is a heterogeneous disease of which we have limited
understanding of the mechanisms that contribute to initiation and
progression of the structural and functional abnormalities in the
pulmonary vasculature (Galie et al. 2004; Sastry 2006; Traiger
2007). Its relatively low prevalence also limits the ability to recruit
large numbers of subjects into clinical trials. Accordingly, there are
insufficient data to characterize the effects of treatment on
subgroups of patients with PAH of different etiologies. Tadalafil
was observed to provide clinical benefit in small populations of
patients with Eisenmenger syndrome and other causes of PAH.
Since the study entry criteria of the PHIRST study include several
different causes of PAH, the larger study sample may provide
additional information on subgroup responsiveness.
Clinical potential
Based on the preliminary findings from pilot studies with tadalafil
in patients with pulmonary hypertension, the proven track record
of the related agent sildenafil in PAH, the known similarities in
the molecular and clinical pharmacology of tadalafil and
sildenafil, and the known comparable clinical effects of these
two agents in men with erectile dysfunction, it appears likely
that tadalafil will provide clinical benefit in patients with PAH.
Pending review of the findings of the ongoing PHIRST study,
tadalafil may offer the convenience of once-daily administration
for this patient population.
Tadalafil’s long elimination half-life and once-daily dosage
schedule make this agent a suitable candidate for development in
other chronic diseases in which inhibition of phosphodiesterase
type 5 may provide clinical benefit. Preliminary studies in patients
with chronic heart failure indicate that phosphodiesterase type 5
inhibition is associated with improved hemodynamics,
amelioration of endothelial dysfunction, and improved exercise
tolerance (Katz et al. 2000; Guazzi et al. 2004; Patel & Katz 2005;
Lewis et al. 2007). Chronic phosphodiesterase type 5 inhibition
may also provide clinical benefit in patients with Raynaud’s
phenomenon (Fries et al. 2005).
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